Mather Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$45.7K Buy
414
+136
+49% +$13.1K ﹤0.01% 1186
2026
Q2
$21.8K Hold
278
– – ﹤0.01% 1309
2026
Q1
$18K Buy
+278
New +$19.6K ﹤0.01% 1302
2025
Q4
– Sell
-197
Closed -$14.4K – 1059
2025
Q3
$14.4K Buy
+197
New +$13.1K ﹤0.01% 1188
2025
Q2
– Sell
-197
Closed -$12.6K – 1069
2025
Q1
$12.6K Buy
197
+70
+55% +$4.07K ﹤0.01% 1194
2024
Q4
$6.07K Hold
127
– – ﹤0.01% 1343
2024
Q3
$7.27K Sell
127
-125
-50% -$7.17K ﹤0.01% 1233
2024
Q2
$10.3K Buy
252
+47
+23% +$2.06K ﹤0.01% 1448
2024
Q1
$7.58K Buy
+205
New +$7.68K ﹤0.01% 1271

Other funds holding HALO

Mather Group's HALO Position: Q3 2026 in Review

Mather Group increased its Halozyme (HALO) stake by 49% in Q3 2026, buying an estimated $13.1K and bringing the position to 414 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1186.

Mather Group first reported a position in HALO in Q1 2024 and has held it in 9 quarters since. 141 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Mather Group held 414 shares of Halozyme worth $45.7K as of Q3 2026.
  • Mather Group bought 136 Halozyme shares in Q3 2026, an estimated $13.1K.
  • Halozyme made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1186 holding.
  • Mather Group first reported a position in Halozyme in Q1 2024 and has held it in 9 quarters since.
  • 141 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.